Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720484 · ClinicalTrials.gov registry record · Phase 2
Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02720484 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 10 participants.
The verdict
NCT02720484, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The primary objective will be to assess overall response rate of nivolumab in patients with metastatic or locally advanced adrenocortical carcinoma. Nivolumab was recently approved by U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma, non-small cell lung cancer and renal cell carcinoma. It is considered investigational for the treatment of advanced or refractory adrenocortical carcinoma. "Investigational" means that the drug is not approved by the USFDA or not approved for the indication under investigation. Nivolumab could shrink adrenocortical carcinoma but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer and hopefully to relieve symptoms that are related to the cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-03-30 |
| Est. Completion | 2018-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02720484
The ClinicalTrials.gov registry entry for NCT02720484 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02720484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02720484 about?
NCT02720484 is a clinical study titled "Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer". The primary objective will be to assess overall response rate of nivolumab in patients with metastatic or locally advanced adrenocortical carcinoma. Nivolumab was recently approved by U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma, non-small cell lung cancer and renal...
What is the current status of trial NCT02720484?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-03-30. Estimated completion is 2018-11-02.
What interventions are being tested in trial NCT02720484?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02720484?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.